Epicrispr secures $90M after early data on epigenetic FSHD treatment
Epicrispr Biotechnologies has raised $90 million for its Series C round after sharing promising early data around a potential new way to treat a rare muscle disease called facioscapulohumeral muscular dystrophy. The Series C was ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.